About Tempero Bio

The startup develops targeted pharmacological therapies for treating substance use disorders, utilizing evidence-based approaches to enhance patient adherence and recovery outcomes. By addressing the barriers to effective treatment, the company enables individuals struggling with addiction to achieve sustainable recovery and improved quality of life.

```xml <problem> Substance use disorders affect millions, yet a significant treatment gap exists due to limited therapeutic options and challenges in patient adherence. Current treatments often fail to address the underlying neurobiological mechanisms of addiction, leading to high relapse rates. There are no FDA-approved medications for stimulant use disorders like cocaine use disorder. </problem> <solution> Tempero Bio is a clinical-stage biopharmaceutical company developing targeted pharmacological therapies to treat substance use disorders by modulating glutamate signaling in the brain. Their lead drug candidate, TMP-301, is a potent, orally-available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) being investigated for cocaine and alcohol use disorders. TMP-301 is designed to reduce excessive glutamate signaling, a key factor in addiction, and has shown promise in preclinical studies. By addressing the neurobiological basis of addiction, Tempero Bio aims to provide more effective treatments that reduce relapse rates and improve patient outcomes. </solution> <features> - TMP-301: A selective mGluR5 negative allosteric modulator (NAM) designed to dampen, but not block, glutamate signaling in specific brain regions associated with substance abuse. - Orally available drug candidate. - Lead indication in the treatment of cocaine use disorder (CUD). - Also being researched for the treatment of alcohol use disorder (AUD), opioid use disorder (OUD), and polysubstance use disorder (PUD). - A Phase 1 study of TMP-301 in healthy volunteers is expected to begin in Q1 2023. </features> <target_audience> The primary target audience includes individuals with substance use disorders, particularly cocaine and alcohol use disorders, and the healthcare providers who treat them. </target_audience> ```

What does Tempero Bio do?

Where is Tempero Bio located?

Tempero Bio is based in Oakland, United States.

When was Tempero Bio founded?

Tempero Bio was founded in 2020.

How much funding has Tempero Bio raised?

Tempero Bio has raised 11660000.

Location

Oakland, United States

Founded

2020

Funding

11660000

Employees

2 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Tempero Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

temperobio.com 200+

Founded 2020 – Oakland, United States

Funding

Estimated Funding

$10M+

Team (<5)

No team information available.

Company Description

Problem

Substance use disorders affect millions, yet a significant treatment gap exists due to limited therapeutic options and challenges in patient adherence. Current treatments often fail to address the underlying neurobiological mechanisms of addiction, leading to high relapse rates. There are no FDA-approved medications for stimulant use disorders like cocaine use disorder.

Solution

Tempero Bio is a clinical-stage biopharmaceutical company developing targeted pharmacological therapies to treat substance use disorders by modulating glutamate signaling in the brain. Their lead drug candidate, TMP-301, is a potent, orally-available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) being investigated for cocaine and alcohol use disorders. TMP-301 is designed to reduce excessive glutamate signaling, a key factor in addiction, and has shown promise in preclinical studies. By addressing the neurobiological basis of addiction, Tempero Bio aims to provide more effective treatments that reduce relapse rates and improve patient outcomes.

Features

TMP-301: A selective mGluR5 negative allosteric modulator (NAM) designed to dampen, but not block, glutamate signaling in specific brain regions associated with substance abuse.

Orally available drug candidate.

Lead indication in the treatment of cocaine use disorder (CUD).

Also being researched for the treatment of alcohol use disorder (AUD), opioid use disorder (OUD), and polysubstance use disorder (PUD).

A Phase 1 study of TMP-301 in healthy volunteers is expected to begin in Q1 2023.

Target Audience

The primary target audience includes individuals with substance use disorders, particularly cocaine and alcohol use disorders, and the healthcare providers who treat them.